CD80 and neoplasm: Although Moc2 is a poorly radioimmunogenic tumor (16, 17), Moc2 tumors exhibited an increase in CD103+ DC but not CD11b+ DC co-expressing CD40 and CD80 in the TdLN after radiation therapy (Fig S5B i and ii and C i and ii).